This Article Full Text Full Text (PDF) All Versions of this Article: 146/8/3235    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morony, S. Articles by Kostenuik, P. J. Search for Related Content PubMed PubMed Citation Articles by Morony, S. Articles by Kostenuik, P. J.

The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

Metabolic Disorders Research (S.M., K.W., S.A., F.A., Z.G., M.G., H.L.T., C.C., C.R.D., P.J.K) and Cancer Biology (C.S., B.W.), Amgen, Inc., Thousand Oaks, California 91320-1789

Address all correspondence and requests for reprints to: Dr. Paul J. Kostenuik, Metabolic Disorders Research, M/S 15-2-B, Amgen, Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1789. E-mail: paulk{at}amgen.com.

Humoral hypercalcemia of malignancy (HHM) is mediated primarily by skeletal and renal responses to tumor-derived PTHrP. PTHrP mobilizes calcium from bone by inducing the expression of receptor activator for nuclear factor-B ligand (RANKL), a protein that is essential for osteoclast formation, activation, and survival. RANKL does not influence renal calcium reabsorption, so RANKL inhibition is a rational approach to selectively block, and thereby reveal, the relative contribution of bone calcium to HHM. We used the RANKL inhibitor osteoprotegerin (OPG) to evaluate the role of osteoclast-mediated hypercalcemia in two murine models of HHM. Hypercalcemia was induced either by sc inoculation of syngeneic colon (C-26) adenocarcinoma cells or by sc injection of high-dose recombinant PTHrP (0.5 mg/kg, sc, twice per day). In both models, OPG (0.2–5 mg/kg) caused rapid reversal of established hypercalcemia, and the speed and duration of hypercalcemia suppression were significantly greater with OPG (5 mg/kg) than with high-dose bisphosphonates (pamidronate or zoledronic acid, 5 mg/kg). OPG also caused greater reductions in osteoclast surface and biochemical markers of bone resorption compared with either bisphosphonate. In both models, hypercalcemia gradually returned despite clear evidence of ongoing suppression of bone resorption by OPG. These data demonstrate that osteoclasts and RANKL are important mediators of HHM, particularly in the early stages of the condition. Aggressive antiresorptive therapy with a RANKL inhibitor therefore might be a rational approach to controlling HHM.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				R. E. Miller, D. Branstetter, A. Armstrong, B. Kennedy, J. Jones, L. Cowan, J. Bussiere, and W. C. Dougall Receptor Activator of NF-{kappa}B Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection J. Immunol., July 1, 2007; 179(1): 266 - 274. [Abstract] [Full Text] [PDF]

				S. Khosla Magic Bullets to Kill Nasty Osteoclasts Endocrinology, August 1, 2005; 146(8): 3233 - 3234. [Full Text] [PDF]